Shandong Galaxy Bio-Tech Co., Ltd-Wuhan Meiyue, a wholly-owned subsidiary of Wuhan Qirui Pharmaceutical Co., Ltd.
On December 1, 2017, Shandong Galaxy Bio-Tech Co., Ltd. and Shanghai Meiyue Bio-Technology Development Co., Ltd. reached a strategic cooperation agreement in Wuhan Qirui Pharmaceutical Headquarters. Shanghai Meiyue Biotechnology Development Co., Ltd. is a wholly-owned subsidiary of Wuhan Qirui Pharmaceutical. Yang Jinkui, chairman of Shandong Yinhe Biotechnology Co., Ltd., and Wang Chaodong, chairman of Wuhan Qirui Pharmaceuticals, witnessed the signing ceremony.
At the strategic cooperation signing ceremony, Shandong Galaxy Bio-Tech Co., Ltd. and Shanghai Meiyue Bio-Technology Development Co., Ltd. have established a new type of strategic cooperative relationship. The two parties will carry out in-depth exchanges and cooperation in the areas of pharmaceutical product development and biotechnology.
Galaxy will conduct trial, verification, trial production and production of ornithine hydrochloride (intermediates), daptomycin (medical raw materials) and other products. Galaxy will upgrade from a cosmetic and food-grade raw material production enterprise to a pharmaceutical-grade raw material production enterprise.
Shandong Galaxy Bio-Tech Co., Ltd. Chairman Yang Jinkui
Wang Qidong, chairman of Wuhan Qirui Pharmaceutical
Both companies celebrated with champagne
Responsible individuals from both companies stated that in the future, the two companies will conduct in-depth and comprehensive cooperation, work hand in hand to work on the cause of human health, carry forward the enterprising, enterprising, and enterprising spirit of innovation, promote the development and inheritance of the biotechnology field, and strive to push forward the development strategy of the company. To a newer stage, create a brand-new and win-win situation.